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Abstract: The incorporation of bioinorganics into synthetic
biomaterials is a promising approach to improve the biologi-
cal performance of bone graft substitutes, while still retaining
their synthetic nature. Among these bioinorganics, strontium
ions (Sr21) have reported enhanced bone formation, and a
reduced risk of bone fractures. While previous results have
been encouraging, more detailed studies are needed to fur-
ther develop specific applications. This study demonstrates
the effects of Sr21 on the osteogenic differentiation of human
mesenchymal stromal cells (hMSCs) when introduced as
either a dissolved salt, or incorporated into biomimetic cal-
cium phosphate (CaP) coatings. Upon attachment, hMSCs
seeded in the presence of higher Sr21 concentrations
presented with a more elongated shape as compared to the
controls without Sr21. Both Sr21 as a dissolved salt in the
medium, or incorporated into CaP coatings, positively influ-
enced hMSC alkaline phosphatase (ALP) activity in a dose-
dependent manner. At the mRNA level, the expression of
osteogenic markers ALP, bone sialoprotein, bone morphoge-
netic protein 2, osteopontin, and osteoclacin were increased
in the presence of Sr21, independent of the delivery method.
Overall, this study demonstrates the positive effects of stron-
tium on the osteogenic differentiation of human MSCs, and
supports the use of strontium-incorporated CaPs for bone
regeneration applications. VC 2016 Wiley Periodicals, Inc. J Biomed
Mater Res Part A: 104A: 1946–1960, 2016.
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INTRODUCTION
Despite advances in orthopedic and dental surgery, the clini-
cal management of bone defects continues to present chal-
lenges.1 While autograft remains the gold standard for
treating bone defects, issues such as limited quantity, donor
site morbidity, and the requirement for an additional surgi-
cal site continue to encourage research into alternatives.2
Synthetic bone graft substitutes have provided promising
results to date, with calcium phosphates (CaPs) maintaining
interest2 due to their chemical similarities to the mineral
phase of bone, being itself a nonstoichiometric carbonated
apatite.3 Despite this, the performance of synthetic bone
grafts remains inferior to autograft. Several attempts have
been made to improve the bone healing capacity of CaPs,4
including combining them with growth factors,5–7 cells5,8,9
and inorganic additives.10–12 The incorporation of inorganic
additives such as magnesium (Mg21), copper (Cu21), stron-
tium (Sr21), and fluoride (F2) into synthetic bone grafts, is
gaining popularity as these additives may directly induce
changes in cells, for example via ion channels, potentially
functioning as “synthetic growth factors.” The potential role
of these bioinorganics in bone tissue, and their effects on
bone formation, are comprehensively summarized by Habi-
bovic and Barralet,13 Yang et al.,4 and Boanini et al.10
While many elements have been shown to influence
bone regeneration, the role of strontium is particularly
interesting due to its relatively high presence within healthy
bone. Approximately 98% of the strontium within the body
is found within bone, with its quantity being positively cor-
related to the compressive strength of bone.13 Strontium
ranelate is currently used for treatment and management of
osteoporotic bone,14–17 with its use reported to reduce the
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risk of fracture in postmenopausal osteoporotic bone,14 and
increase bone mineral density.15
To date, several studies have investigated the effects of
local Sr21 delivery on osteogenesis and bone formation.
Promising results have been obtained when strontium was
incorporated into synthetic bone grafts, including bioactive
glasses,18–20 titanium implants,21,22 calcium silicates,23 and
CaPs.1,11,24–30 In vitro studies have previously demonstrated
that strontium incorporation into CaPs resulted in a dose-
dependent effect on osteoblast and osteoclast growth and
activity.11,24–27 This effect has also been demonstrated using
ovariectomized rats, where the ion release from Sr21-doped
CaPs resulted in increased new bone formation28 and
improved osseointegration.29
While the addition of strontium ions to CaP bone graft
substitutes has provided positive results to date, a deeper
understanding of the mechanisms and function of strontium
is still lacking. Such information is needed to convert this
potential into applicable products. To further elucidate the
specific role of strontium in bone healing, this study investi-
gated the effect of Sr21 on hMSCs in two conditions. In the
first condition, Sr21 ions were delivered to the cells as a
dissolved salt, in order to understand its direct effect on
hMSCs. In comparison, and with the aim to assess a degrad-
able CaP as a delivery vehicle for this ion, the second condi-
tion used a two-step biomimetic approach to incorporate
Sr21 at varying concentrations into crystalline CaP coatings,
which were deposited on titanium substrate. For both con-
ditions, cell responses were studied using proliferation and
osteogenic differentiation marker expression, and changes in
hMSC morphology. Overall, this study was undertaken to
elucidate the specific mechanisms of strontium-induced




Commercially pure Titanium (cp Ti grade 4) was used as
a substrate for the CaP coatings. The Ti sheet was cut into
1 3 1 cm2 pieces and grit-blasted using alumina beads
with a diameter of 250 mm to reach a Ra roughness of
1.36 0.1 mm.
A 2-step biomimetic coating approach was used to pre-
pare the coatings, as previously described.11,31 Briefly, the
surface of the Ti plates were coated with a thin amorphous
CaP layer by vertical immersion in a supersaturated simu-
lated body fluid (SBF) for 24 h at 378C. This solution, con-
taining NaCl, CaCl2.2H2O, MgCl2.6H2O, NaHCO3, and
Na2HPO4.2H2O salts (Sigma, Table I) was prepared under
mildly acidic conditions by dissolution of CO2 gas. The pre-
calcified Ti plates were then immersed for 48 h at 378C in a
calcium phosphate solution (CPS) containing NaCl,
CaCl2.2H2O, and Na2HPO4.2H2O salts (Sigma, Table I) that
was buffered at pH 7.4 by addition of tris-
hydrozymethylaminomethane (Tris) and 1M HCL (Sigma). A
stock solution of strontium acetate (Sigma) in a Tris buffer
(pH5 7.4) with concentration of 100 mM was prepared. To
incorporate strontium into CaP coatings, appropriate vol-
umes of Sr21 stock solution were combined with the CPS
solution to reach varying concentrations of Sr21 in CPS (0,
10, and 1000 mM). The CPS solution was refreshed after
24 h. The coatings were then washed three times with
MilliQ water and dried overnight at 378C in an air oven.
Coating characterization
The chemistry of the mineral phase was characterized by
Fourier transform infrared spectroscopy (FTIR, Perkin-
Elmer Spectrum 1000) and X-ray diffraction (XRD, Miniflex,
Rigaku). The morphology of the mineral films, and the pres-
ence and distribution of calcium, phosphorus, and strontium
were investigated scanning electron microscopy (SEM, XL-
30 ESEM-FEG, Philips), coupled with energy dispersive X-
ray spectroscopy analyzer (EDS, EDAX, AMETEK Materials
Analysis Division). Quantification of the data was achieved
using the TEAMTM EDS V2.2 software provided by the EDS
manufacturer. The Ca/P, Sr/P, (Ca1 Sr)/P, and Sr/Ca ratios
were calculated upon analysis.
Additionally, the coatings were dissolved in ultrapure
nitric acid and the Sr21 content of the coating was meas-
ured using inductively coupled plasma mass spectrometry
(ICP-MS, Agilent 7700 ICP-MS, Agilent Technologies).
Cell subculture
hMSCs were isolated from bone marrow aspirates (5–
20 mL) obtained from 2 donors after written informed con-
sent. Isolation procedure and full characterization of the
cells have been described previously.32,33 In short, aspirates
were resuspended using 20 G needles, plated at a density of
5 3 105 cells per cm2, and cultured in proliferation medium
[consisting of a-MEM (Gibco) supplemented with 10% fetal
bovine serum (Lonza), 2 mM L-glutamine (Gibco), 0.2 mM
ascorbic acid (Sigma), 100 U mL21 penicillin and 100
mg mL21 streptomycin (Gibco), and 1 ng ml21 rhbFGF (AbD-
Serotec)]. The medium was refreshed every 2–3 days. Cells
were harvested at 80% confluency for subculture until
they reached passage 3.
Cell culture
In the first step of cell culture, hMSCs of passage 3 from the
2 donors were seeded on treated tissue culture plates
(TCPs) at a density of 10,000 cells/cm2 [for DNA, alkaline
phosphatase (ALP), and qPCR assays] or at 2500 cells/cm2
(for imaging cell morphology) in 50 mL of basic medium
[a-MEM (Gibco) supplemented with 10% fetal bovine serum
(Lonza), 2 mM L-glutamine (Gibco), 0.2 mM ascorbic acid
(Sigma), 100 U ml21 penicillin and 100 mg ml21 streptomy-
cin (Gibco)]. After seeding, 1 mL of either basic or osteo-
genic medium [basic medium supplemented with 10 nM
TABLE I. Ionic Content of Concentrated SBF and CPS
Solutions used for Preparation of the Coatings




733.5 7.5 12.5 720 5 21
CPS 140 0 4 144 2 0
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dexamethasone (Sigma)] was added to each well. Appropri-
ate volumes of Sr21 stock was added to each well to reach
Sr21 concentrations of 0, 10, and 1000 mM in cell culture
medium. The medium was refreshed every 2–3 days.
In parallel, hMSCs of two donors were cultured on
coated Ti plates. CaP coatings were sterilized with ethanol
prior to cell culture. To sterilize, the samples were placed in
a sterile nontreated well plate and washed three times with
70% ethanol followed by 15 min of drying inside the flow
cabinet after each washing step. In the last step of steriliza-
tion, 100% ethanol was added to the samples and allowed
to evaporate in the flow cabinet for at least 2 h. The plates
were then washed twice with sterile PBS, followed by an
overnight incubation in a 5% CO2 humid atmosphere at
378C after the addition of 1 mL basic medium. hMSCs of
passage 3 from 2 donors were seeded on the coated Ti
plates at a density of 10,000 cells/cm2 (for DNA, ALP, and
qPCR assays) or 2500 cells/cm2 (for imaging cell morphol-
ogy) in 50 mL of basic medium and allowed to attach to
the coatings for 4 h, after which 1 mL of either basic or
osteogenic medium was slowly added to each well. The
medium was refreshed every 2–3 days. Cell medium was
collected at each refreshment point and concentrations of
Ca and Sr in basic cell medium were then measured using
ICP-MS, at each refreshment point up to 7 days.
Cell morphology
At day 1 after cell seeding, the cells cultured on TCPs and
CaP coatings were washed with PBS and fixed with a buffer
of 4% paraformaldehyde (pH57.4) for 30 min. The cells
cultured on TCPs and CaP coatings were then permeabilized
with 0.1% Triton X-100 in PBS solution for 10 min, washed
with PBS and blocked for 30 min in a blocking solution (2%
bovine serum albumin and 0.1 v/v% Tween 20 in PBS).
Subsequently, Alexa Fluor 594 antibody (Invitrogen) diluted
in blocking buffer was added to the cells to stain the cell
cytoskeleton, and incubated at room temperature in dark
for 1 hour. After incubation, cells were washed with PBS,
and DAPI antibody (Sigma-Aldrich/Fluka) diluted in PBS
was added for 10 min. The cells were then washed with
PBS and imaged using a fluorescent microscope (E600,
Nikon; the data is not shown for cells cultured on CaP
coatings).
Six pairs of immunofluorescent images obtained in blue
and red channels (for Dapi and Phalloidin antibodies,
respectively) were used for quantifying cell shape parame-
ters. The data was analyzed in CellProfiler software as was
described previously34 and cell area and eccentricity param-
eters were selected to assess the changes in cell morphol-
ogy upon introduction of Sr21. Cell area shows the total
number of pixels located in the cell area. Eccentricity shows
morphological elongation and measures the deviation of a
conic section from a circle, with eccentricity being equal to
zero for a circle and one for a parabola.35
After fixation, the cells cultured on CaP coatings were
also dehydrated by addition of alcohol series (70, 80, 90,
and 100%, 30 min per concentration) and dried using a
critical point drier (CPD 030, Balzers). The samples were
then gold sputtered and imaged using SEM. Two independ-
ent experiments with n5 2 for each condition were
performed.
DNA content and ALP activity quantification
Total DNA was assessed with CyQuant Cell Proliferation
Assay kit (Invitrogen). After 3 freeze/thaw cycles at 2808C,
500 mL lysis buffer (lysis buffer provided in the kit diluted
in a buffer of NaCl-EDTA solution) was added to each well.
The samples were ultra-sonicated and incubated at room
temperature for 1 h. After centrifugation, 100 mL of the
supernatant was mixed with the same volume of CyQuant
GR dye in a 96 well microplate and incubated for 15 min.
Fluorescence measurements for DNA quantification were
done at excitation and emission wavelengths of 480 and
520 nm, respectively, using a spectrophotometer (Perkin
Elmer). ALP activity in the cultures was measured using a
CDP-star kit (Roche Applied Science); 10 mL of the superna-
tant was mixed with 40 mL CDP-star reagent in a 96 well
microplate and incubated for 30 min. After incubation,
chemiluminescence measurements were completed at
466 nm. Results of the DNA assays are presented based on
average mg of DNA detected in each condition. Results of
ALP activity were normalized per DNA content of each cul-
ture and presented as the average of normalized ALP activ-
ity per mg of DNA for each condition. Two independent
experiments with n5 3 for each condition were performed
for DNA and ALP analyses, and the results of one represen-
tative experiment are presented here.
RNA extraction and gene expression (qPCR) assay
Total RNA was isolated by using a NucleoSpinVR RNA II iso-
lation kit (Macherey Nagel) for cells cultured on TCPs and
in combination with NucleoSpinVR RNA II isolation kit and
Trizol method, in accordance with the manufacturer’s proto-
col. RNA was collected in RNAse-free water and the total
concentration was measured using nano-drop measurement
equipment (ND1000 spectrophotomer, Thermo Scientific).
The cDNA of the cultures were then prepared using an
iScript kit (Bio-Rad) according to the manufacturer’s proto-
col and diluted 10 times in RNAse-free water to be used for
quantitative real-time PCR (qPCR). The qPCR measurements
were completed using Bio-Rad equipment using Syber green
I master mix (Invitrogen) and the primer sequences
(Sigma), which are listed in Table II. Expression of the
osteogenic marker genes were normalized to GAPDH levels
and fold inductions were calculated by using DDCT method.
hMSCs cultured on TCPs in basic medium for 7 days were
used as calibrator. Two independent experiments with n5 3
for each condition were performed for the qPCR analysis,
and the results of one representative experiment are pre-
sented here.
Statistical analysis
Statistical comparisons were performed using One-way
Analysis of Variance (ANOVA) followed by a Tukey’s multi-
ple comparison post-hoc test. Error bars indicate one
1948 BIRGANI ET AL. HMSC RESPONSE TO BIOMIMETIC OCP CONTAINING SR21




The 2-step biomimetic technique employed for preparation
of the CaP coatings resulted in the formation of a uniform
crystalline CaP layer that covered the entire surface of the
Ti plates [Fig. 1(a–c)]. The SEM micrographs showed CaP
crystals with a plate-like morphology, which formed perpen-
dicular to the surface of the Ti plates. The morphology of
the crystals was modified by addition of Sr21 to the initial
CPS solution. Sr21-added CPS solution resulted in smaller
and less sharp CaP crystals [Fig. 1(c)].
The presence of the CaP film was confirmed by EDS
spectra of the samples, in which sharp peaks of calcium,
phosphorous, and oxygen were visible [Fig. 1(d–f)]. EDS ele-
mental maps also showed that Ca and P elements were
homogeneously distributed on the surface [Fig. 1(g–l)]. EDS
results showed presence of Sr21 in the CaP coatings pre-
pared with a concentration of 1000 mM Sr21 in the CPS
solution [Fig. 1(f)]. The EDS strontium elemental maps indi-
cated that Sr21 was homogeneously distributed within the
coating [Fig. 1(m–o)]. Quantification of the EDS results indi-
cated an incorporation of approximately 3 at% of strontium
into CaP coatings at the highest concentration of Sr21 in
CPS solution (Table III). EDS did not detect Sr21 in the coat-
ing with low Sr21 incorporation. However, ICP measure-
ments showed the presence of 0.44 and 16.49 mg/l Sr21 in
the coatings with low and high incorporation of Sr21 dis-
solved in HNO3, respectively (Table III). Comparing the mea-
surement method averages, the ICP measured Sr/Ca at%
ratio as 0.01, 0.22, and 10.32, whereas the EDS measured
the Sr/Ca at% ratio as 1.75, 1.88, and 8.89, for the OCP Sr0,
OCP Sr10, and OCP Sr1000, respectively. Calculation of
atomic ratios indicated that the ratio of Sr/P increased from
0.021 to 0.098 by increasing the concentration of Sr21 in
CPS solution from 0 to 1000 mM. The Ca/P ratio in these
conditions, however, was calculated to be 1.197 and 1.091,
respectively. The (Ca1 Sr)/P ratios remained constant at
1.2.
The results of the XRD and FTIR analyses for CaP coat-
ings without and with Sr21 (Fig. 2) were in accordance with
data obtained in earlier studies when similar biomimetic
coating method was applied.36–38 The XRD patterns [Fig.
2(a)] of the coatings exhibited peaks at 2h 54.78 corre-
sponding to (010) diffraction line and at 2h 5 25.88 corre-
sponding to (002) plane, both typical of triclinic
octacalcium phosphate (OCP) crystals. The peaks observed
at 2h 59.88 and at 2h 5 27-28.58 can also be attributed to
the OCP structure. The broad set of peaks at 2h 5 31.58 to
32.58 are common for both OCP and apatitic structures. A
small shift of 2h 5 0.18 toward lower degrees was
observed in some of the characteristic OCP peaks, when the
OCP Sr1000 coating was analyzed. Supporting Information
Figure S1 summarizes the position of the main peaks in the
XRD patterns of the coatings without and with Sr21
incorporation.
The FTIR spectra of the coatings [Fig. 2(b)] exhibited
sharp P-O bands at 560 and 600 cm21. Moreover, the bands
at 906 and 850 cm21 were typical HPO224 bands in the OCP
phase. Nevertheless the vibration bands observed between
1020 and 1070 cm21 were less sharp and less numerous as
compared to phase-pure OCP.37,38 The small bands observed
at 1450 and at 1480 cm21 corresponded to the carbonate
group typical of A-B carbonated apatite, suggesting that
apart from the OCP, the coating comprised a carbonated
apatitic phase. The typical PO324 and HPO
2
4 bands of the
coatings prepared in presence of higher concentration of
Sr21 were less sharp, suggesting a decrease in crystallinity.
Cell morphology
Cells cultured on TCPs with 1000 mM Sr21 in the basic
medium appeared to have a higher aspect ratio compared
to cells cultured in basic medium without Sr21 addition,
while no apparent differences were observed between
the control, and the cells treated with 10 mM of Sr21
[Fig. 3(a–c)].
Quantification of the cell parameters using CellProfiler
based on immunofluorescent images showed that the cell
area was reduced dose-dependently when Sr21 was added
to cell medium. The eccentricity was, however, significantly
increased upon addition of Sr21 to cell medium in a dose-
dependent manner, confirming increase in elongation of the
cells treated with Sr21.
Similar results were obtained when cells were cultured
on OCP coatings. After 1 day, cells cultured on OCP Sr1000
coatings appeared more elongated in their morphology com-
pared with the cells cultured on OCP and OCP Sr10 coatings
[Fig. 4(d–f)]. The adhesion points were observed in the cells
cultured on all the coatings [Fig. 3(g–i)].
Quantification of the morphology parameters of the cells
cultured on CaP coatings based on immunofluorescent
images indicated that area of the cells cultured on OCP Sr10
was significantly higher than the area of those cultured on
OCP without strontium incorporation. The eccentricity of
cells cultured on OCP Sr1000 was also significantly higher
than the one of the cells cultured on OCP and OCP Sr10
coatings.
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DNA content and ALP activity
At 7 days, the addition of 1000 mM Sr21 to the osteogenic
media increased the hMSC DNA content in both donors
when cultured on TCPs, however, this increase was only sig-
nificant in cells of Donor 1. A similar trend was seen when
1000 mM of Sr21 was added to basic media in Donor 1 cul-
tures, but not when cells from Donor 2 were cultured [Fig.
4(a,b)]. The DNA content of the cells did not increase
between 7 and 14 days, suggesting the formation of a con-
fluent monolayer before the second time point analysis.
While at 7 days, no significant differences in ALP activity
were seen among the conditions, at 14 days, the addition of
either 10 or 1000 mM Sr21 to osteogenic media increased
the normalized ALP activity of hMSCs. This result was statis-
tically significant for cells of Donor 1, and for 1000 mM in
Donor 2 cells [Fig. 4(c,d)].
No differences in DNA content were seen when cells
were cultured on coatings for 7 days, however, at 14 days
in Donor 2 cells, the incorporation of Sr21 into OCP
increased the DNA content, with this result being
FIGURE 1. SEM images (a,b,c), EDS spectra (d,e,f), Ca elemental map (g,h,i), P elemental map (j,k,l) and Sr elemental map (m,n,o) of OCP, OCP
Sr10, and OCP S1000, respectively. A crystalline CaP layer was formed on the surface of Ti plates with a homogenous distribution of all the ele-
ments. Presence of Sr21 in higher concentration was detected in EDS spectrum and Sr elemental map of OCP Sr1000. Moreover, the morphol-
ogy of the coatings changed upon addition 1000 m Sr21 to CPS solution resulting in smaller and less sharp crystals.
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statistically significant for both basic and osteogenic media
at both incorporation concentrations. This effect, however,
was not observed in Donor 1 cells. A difference in prolifera-
tion profile was observed between the cells from the two
donors, with an increase in DNA content between day 7 and
day 14 for the cells from Donor 2 but not for the Donor 1
cells [Fig. 5(a,b)].
At 14 days, the incorporation of Sr21 into OCP at the
higher concentration (OCP Sr1000) increased the ALP activ-
ity in Donor 1, with this result being statistically significant
in both basic and osteogenic media. This effect was also
observed in osteogenic medium in Donor 2 cells [Fig.
5(c,d)].
Expression of osteogenic markers at mRNA level
While in basic medium, no significant differences in ALP
mRNA expression of cells cultured on TCPs were observed
among the conditions at either time point, at 7 days, the
addition of 1000 mM of Sr21 to the osteogenic media signifi-
cantly increased the ALP expression in Donor 1 cells. At 14












(Ca 1 Sr)/P ratio
Measured
by EDS
OCP Sr0 0.780 0.024 1.197 0,021 1,218
OCP Sr10 0,698 0.444 1,168 0,021 1,189
OCP Sr1000 2.964 16.490 1.091 0,097 1,189
The Sr content in OCP Sr1000 was 3 at%, whereas the content of both OCP and OCP Sr10 coating was within the background noise,
below 1 at%. Increasing the concentration of Sr21 in CPS solution resulted in increasing in Sr/P and a slight decrease in the Ca/P ratios, while
(Ca 1 Sr)/P ratio constantly remained at 1.2.
FIGURE 2. XRD patterns (a) and FTIR Spectra (b) of the coatings. The XRD patterns and the FTIR spectra suggested that the coatings predemi-
nantly consisted of OCP, with presence of some carbonated apatite. Furthermore, the data suggested that an increase of Sr21 content of the
coating led to a limited decrease in crystallinity.
ORIGINAL ARTICLE
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FIGURE 3. Fluorescent microscopy images of the cells cultured for 1 day on TCPs in basic medium without 0 (a), and supplemented with 10 (b)
or 1000 (c) mM Sr21, quantification of cell area (d) and eccentricity (e) of these cells, SEM images of the cells cultured for 1 day in basic medium
on OCP (f), OCP Sr10 (g), and OCP Sr1000 (h) coatings with (i–k) magnified images of the areas marked with dashed lines in (f–h) images,
respectively, and quantification of cell area (l) and eccentricity (m) of these cells. In fluorescent images, the cells were stained with Dapi (in blue)
and Phalloidin (in green) showing cell nuclei and cytoskeleton, respectively. Cells cultured with 1000 mM Sr21 appeared to have a higher aspect
ratio compared with cells cultured without Sr21 and with addition of 10 mM Sr2. Cells cultured on OCP Sr1000 coatings were more elongated
compared with the cells cultured on OCP and OCP Sr10 coatings. Quantification of eccentricity of the cells confirms these results.
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FIGURE 4. DNA content (a, c) and ALP activity (b, d) of hMSCs of, respectively, Donor 1 and Donor 2 cultured on TCPs. Sr21 supplementation in
cell culture medium slightly increased the DNA content of the Donor 1 cells at day 7, while no differences were observed for the other condi-
tions. At day 14, addition of Sr21 to osteogenic medium resulted in increasing ALP activity of hMSCs in a dose-dependent manner.
FIGURE 5. DNA content (a, c) and ALP activity (b, d) of hMSCs of, respectively, Donor 1 and Donor 2 cultured on the coatings. At day 14, an increase in
DNA content of the cells of Donor 2 was observed upon incorporation of Sr21 into the coatings. At day 14, addition of Sr21 to either medium in cultures
of Donor 1 cells and to osteogenic medium in cultures of Donor 2 cells resulted in an increase in ALP activity in a strontium dose-dependent manner.
ORIGINAL ARTICLE
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days, the addition of Sr21 to osteogenic media increased the
ALP expression, however, this effect was not consistent
between the donors [Fig. 6(a,b)].
At day 7, no differences among the conditions were
observed in the bone sialoprotein (BSP) expression when
cells were cultured on TCPs in basic medium. However, at
day 14, Sr21 supplementation in both basic and osteogenic
media resulted in an ascending trend in expression of BSP
dependent on Sr21 dose, with a significant effect in osteo-
genic medium in donor 1 and in basic medium in donor 2
cells [Fig. 6(c,d)].
At days 7 and 14, the addition of Sr21 to basic media
only appeared to influence bone morphogenetic protein 2
(BMP2) expression, however, this result was statistically sig-
nificant only between 0 and 1000 mM in Donor 1, and 10
and 1000 mM in Donor 2. A similar trend was observed in
osteopontin (OP) expression in basic media, with significant
difference between 10 and 1000 mM in Donor 2 cells. The
addition of 1000 mM to osteogenic media significantly
increased OP expression in Donor 1, however, this result
was not observed in Donor 2 cells [Fig. 6(e,f)].
No significant differences among the conditions were
observed in OC expression at 7 days in either medium. At
day 14, the addition of Sr21 to both basic and osteogenic
media appeared to decrease OC expression in a dose
dependent manner in donor 1; however, this result was
statistically significant only in osteogenic medium. Unlike in
Donor 1 cells, the OC expression by the cells of Donor 2
was significantly increased upon addition of 1000 mM of
Sr21 to basic medium at day 14, while no effect was seen in
osteogenic medium [Fig. 6(g–j)].
At day 14, hMSCs of donor 1 only, cultured on OCP
Sr1000 expressed slightly higher ALP mRNA levels com-
pared with the cells cultured on OCP and OCP Sr10 in basic
medium. A similar effect was detected in osteogenic
medium, however, this was only significant between OCP
and OCP Sr1000. [Fig. 7(a,b)].
Differences in the expression of BSP of cells cultured on
different coatings were only observed for Donor 1. At days
7 and 14, incorporation of Sr21 into OCP coatings increased
the expression of BSP in basic medium in a dose-dependent
manner [Fig. 7(c,d)].
While low BMP2 levels were observed for all conditions
in osteogenic medium, at day 14, hMSCs of donor 1 cultured
on OCP Sr1000 coating showed higher BMP2 expression
compared to the ones cultured on OCP and OCP Sr10 in
basic medium. A similar effect, however not significant, was
observed in donor 2 as well [Fig. 7(e,f)].
Similar to BMP2, expression of OP was low in osteogenic
medium in all the conditions. At day 14, expression of OP in
basic medium was higher in OCP Sr1000 coatings compared
to OCP and OCP Sr10 in donor 1. A similar, but non-
significant effect was observed in donor 2 at similar condi-
tions [Fig. 7(g,h)].
While at 7 days, no significant differences were
observed, at day 14, in donor 1, higher OC levels were seen
in both media when cells were cultured on OCP Sr1000
coatings compared to OCP and OCP Sr10, however, in basic
medium this effect was only significant between OCP
Sr1000 and OCP Sr10. In donor 2, OC was upregulated in
osteogenic medium in the cells cultured on OCP Sr1000
compared to the cells cultured on OCP and OCP Sr10 [Fig.
7(i,j)].
Ion concentrations in cell medium
Concentrations of Ca21 and Sr21 ions in basic medium up
to day 7 were measured using ICP-MS (Table IV). Ca21 con-
tent of control cell culture medium, not containing cells or
coatings, slightly decreased after 2 days. However, this con-
centration reached the original values at later time points. A
major decrease of >1 mM in Ca21 content of cell medium
incubated with CaP coatings cultured with cells was
detected after 2 days of culture. Ca21 content of the
medium remained constant at this level at later time points.
This effect was independent of Sr21 incorporation.
A Sr21 release of 12 mM was observed in cell medium
conditioned with OCP Sr1000 mM after 2 days. The Sr21
release was calculated as 5 and 2 mM for 4 and 7 days,
respectively. The Sr21 release was negligible in the medium
conditioned with OCP and OCP Sr10 samples.
DISCUSSION
Among the trace elements within bone mineral, strontium is
of particular interest due to its reported osteogenic and
antiresorptive effects.16,17 Pasqualetti et al. suggested that,
while absolute levels of strontium influence the embryonic
mineralization, the actual strontium-to-calcium ratio may
also have an important role in the mineralization process.39
In addition to the chemical interplay, strontium has been
suggested to influence cellular responses by affecting the
physicochemical properties of the mineral.11 In this manner,
strontium ranelate is thought to prevent osteoporotic frac-
tures via an increase in bone hardness due to the Sr21 ionic
substitution.40,41 To further develop strontium-based treat-
ments, the exact mechanisms of strontium’s actions are yet
to be fully elucidated.
In this study, a biomimetic approach was taken to pre-
pare strontium-incorporated CaP coatings on Ti substrates.
The results indicated that a predominantly crystalline OCP
layer formed which was not inhibited by the lower concen-
tration of strontium, though the crystal morphology was
influenced at higher strontium concentrations. The presence
of strontium was confirmed using EDS and ICP-MS analyses.
The decrease in the Ca/P ratio, and increase in the Sr/P
ratio, with a constant (Ca1 Sr)/P ratio of 1.2 were
observed. While the calculated ratio of Ca/P of 1.2 in this
study differs to the theoretical OCP value of 1.33, this value
may have been affected by the semi-quantitative nature of
the elemental analysis used. Additionally, the FTIR data indi-
cated the presence of carbonate bands, suggesting the coat-
ing formed was not phase-pure. Further, when compared to
the coatings formed in absence of Sr21 ions, the small shift
to smaller angles was observed in the XRD pattern of OCP
Sr1000 coatings, which may be due to the incorporation of
strontium ions into the OCP lattice, as shown earlier.42 This
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FIGURE 6. mRNA expression of ALP (a,b), BSP (c,d), BMP2 (e,f), OP (g,h), and OC (i,j) by, respectively, hMSCs of Donor 1 and Donor 2 cultured
on TCPs. The results are normalized for the mRNA level of GAPDH as a housekeeping gene and calibrated for the mRNA level of each gene of
hMSCs cultured in basic medium without supplementation for 7 days. mRNA expression of all the osteogenic markers was altered upon addi-
tion of Sr21 to cell culture medium. Sr21 ions generally increased the expression of ALP, BSP, BMP2, and OP, with comparable trends in both
donors. Opposing trends were, however, observed in the expression of OC from Donor 1 and Donor 2 cells.
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FIGURE 7. mRNA expression of ALP (a,b), BSP (c,d), BMP2 (e,f), OP (g,h), and OC (i,j) by respectively hMSCs of Donor 1 and Donor 2 cultured
on CaP coatings. The results are normalized for the mRNA level of GAPDH as a housekeeping gene and calibrated for the mRNA level of each
gene in hMSCs cultured in basic medium on OCP coating for 7 days. In general, presence of Sr21 in the CaP coatings positively affected the
expression of osteogenic markers. Similar trends were observed in the two donors, with the effects being stronger in Donor 1 cells.
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shift however may also be due to broadening of the diffrac-
tion peaks upon addition of the Sr21 or the overall struc-
tural change toward a more apatitic phase resulting in
modification of the XRD pattern. Therefore, physical entrap-
ment of strontium acetate or another strontium salt into the
coating during deposition cannot be fully excluded. Regard-
less, this data proved the formation of an OCP phase with
varying Sr21 content, which was directly dependent on the
impregnation concentration of Sr21.
The results indicated a release of strontium from OCP
Sr1000 coatings into basic cell medium at 12, 5, and 3 mM
after 2, 4, and 7 days, respectively. A relatively high release
of Sr21 after 2 days was accompanied by a pronounced
uptake of Ca21 ions from the medium, while at the later
time points, the Ca21 concentration remained constant, and
release of Sr21 decreased. This may have been due to repre-
cipitation of a new biological apatite layer formed through
dissolution/reprecipitation events occurring on the coating
surface.43 The maximum amount of strontium in the pre-
pared OCP coatings was 8.9% of the calcium content,
which aligns with the percentage reported for a similar
method of production.11 These values are also in the range
reported for that of human bone, being 3.9 at%.44 However,
due to ion release via CaP dissolution, it is difficult to relate
total incorporated percentage to the actual ion concentra-
tion exposed to the cell.
Cytoskeletal components such as actin have been
reported to be involved in mediating hMSC proliferation and
differentiation toward osteogenic lineage, with early cytos-
keletal organization reportedly having a major effect on cell
fate.45 Barradas et al.,46 for example, have shown that the
Ca21 induced morphological changes initially occurred in
the cytoskeleton as early as after 12 h. Therefore, we have
selected a 24 h time point for studying the early morpho-
logical organization induced by Sr21.
The presence of strontium appeared to influence cell
shape, with a more elongated morphology observed as com-
pared to cells cultured in absence of strontium. In particu-
lar, a dose-dependent effect on cell eccentricity was
detected upon increasing strontium concentration. Similar
changes in eccentricity have previously been identified as
important parameters for interpreting changes in cellular
responses.35 In this study, elongated cells generally corre-
sponded to a higher expression of osteogenic markers at
mRNA level. While changes in cell morphology are often
considered to relate to cell fate, the morphology corre-
sponding to specific lineages remains uncertain.45–48 As
such, while shape differences were noted in this study, fur-
ther investigation is needed to provide a more detailed con-
text for these results.
A different trend in the changes in cell area as a func-
tion of Sr21 content was observed on TCPs as compared to
the CaP coatings. This could in a part be explained by lower
levels of Sr21 released from the coatings, as compared to
the Sr21 conditioned media. Furthermore, the cell microen-
vironment provided by the CaP coatings included the pres-
ence of other ions, as well as the topographical cues of the
substrate surface, which is substantially different from that
of the cultures on TCPs.
The addition of strontium appeared to influence the
DNA production of hMSCs, which is considered an indicator
of cell proliferation. However, these changes were relatively
small, being less than two-fold. Sr21 ions have previously
shown to increase the proliferation of human osteoblasts,49
and increase the production of collagen matrix in murine
preosteoblast cells.50 Therefore, enhancing the proliferation
and survival of bone forming cells has been proposed as a
mechanism in which Sr21 favors bone formation.4,51 While
the results did not reject this hypothesis, this study could
did not strongly support this statement.
ALP enzyme activity of hMSCs was generally increased
upon exposure to Sr21 ions via both delivery methods,
although there was some variation between donors. This
finding is consistent with previously reported data.25–27,49,50
The effect of strontium on the expression of osteogenic
markers at the mRNA level appeared to be dose dependent.
This suggests that within the limits of this study, a higher
dose of strontium used was favorable. This result aligns
with previously published data, in which strontium was
reported to have a dose dependent effect on the ALP activ-
ity of hMSCs.27,49,52 Similarly, Brennan et al.49 and Bonnelye
et al.16 detected the biologic effects of Sr21 in the form of
strontium ranelate on osteogenic markers at a minimum
concentration of 1000 mM. Therefore, strontium release and
dose should be considered in future strategies.
The expression of osteogenic markers was also highly
dependent on the medium used. Generally, expression of
BMP2, OP, and OC was higher in basic medium, whereas
TABLE IV. Ca21 and Sr21 Concentration of Basic Medium Collected During the Culture of hMSCs on CaP Coatings with, as a
Control, Basic Medium Without Materials or Cells
Day

















0 1720.50 0.55 1720.50 0.55 172.50 0.55 1720.50 0.55
2 1226.97 0.57 790.99 0.33 769.39 0.48 820.54 12.22
4 1373.85 0.61 773.75 0.34 707.84 0.40 735.46 5.02
7 1757.04 0.69 769.44 0.60 714.88 0.37 770.47 3.22
A decrease of Ca21 concentration was observed after 2 days in all the samples, after which a plateau at about 700 mM was reached. A
release of 12, 5, and 3 mM Sr21 after 2, 4, and 7 days, respectively, was detected during cell culture of OCP Sr1000, suggesting dissolution/repre-
cipitation events occurring on the coating surface.
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ALP and BSP genes were more highly expressed in osteo-
genic medium. The osteogenic medium used in this study
contained 10 nM dexamethasone, a concentration previously
shows to be optimal for formation of mineralized nodules in
human osteoblast precursor cell culture.53 At this concentra-
tion, dexamethasone has also been reported to increase the
expression of ALP and RUNX2 of human primary bone cells
at mRNA and protein level.46,53–55 Conversely, evidence
exists for the negative effects of glucocorticoids, such as
dexamethasone, on bone mineralization, which may lead to
lower bone mineral density.56 Wiontzek et al. also demon-
strated the inhibitory effects of dexamethasone, in which
intracellular Ca21 concentration increased in MG63 shortly
after dexamethasone treatment.57 It appears that in this
study, the addition of dexamethasone to cell medium inhib-
ited the regulatory effects of Ca21, resulting in down-
regulation of Ca21-dependent osteogenic markers including
BMP2, OP and OC.46 Sr21 ions, as a divalent cation similar
to Ca21, may act on similar cellular targets as Ca21, and
similar effects are expected to occur.46
Generally, hMSCs cultured on OCP coatings with and
without Sr incorporation had a higher expression of BMP2,
OP, and OC, and lower expression of ALP and BSP, when
compared cells cultured on TCPs in Sr-supplemented media.
This is likely due to the regulatory effects of Ca21 ions on
BMP2, OP, and OC expression. The Ca21 level in cell medium
containing the different coatings was similar and independ-
ent of Sr21 incorporation, while the Sr21 concentration dif-
fered, which may explain differences in the expression of
the osteogenic markers in coatings with and without stron-
tium and suggests the combined effects of both ions. This is
further highlighted by the fact that, while the medium con-
centration of strontium was similar between the OCP
Sr1000 and 10 mM Sr21 supplemented media, the hMSC
response in these conditions was very different. The expres-
sion of BMP2, OP, and OC in OCP Sr1000 was substantially
higher than that for the cells cultured with 10 and 1000 mM
Sr21 salt, indicating a combinatory effect of strontium and
calcium ions on the osteogenic markers, which are known
to be Ca21-dependent. As expected, such an effect was not
observed on ALP and BSP expression, even when the pres-
ence of strontium in the coatings resulted in upregulating
these genes.
It is worth mentioning that the expression of the osteo-
genic markers at mRNA level does not necessarily translate
to production of these proteins. Therefore, the study of the
effects of Sr21 addition to the CaPs on production of the
osteogenic matrix proteins is recommended for future
experiments.
It should be noted that changes in calcium content of
the medium in presence of OCP coating are expected to be
accompanied by the changes in inorganic phosphate concen-
tration, also known to affect the hMSCs behavior58 and
this effect needs further investigation. Furthermore,
possible direct effects of changes in crystal structure upon
incorporation of strontium into the coating require
further investigation, since the cell fate can be affected by
the physical properties of the material surface,59 such as
roughness, microporosity and macroporosity,60 grain size,61
and topography.49,50,62
CONCLUSION
This study confirms that strontium promotes the osteogenic
differentiation of bone marrow derived hMSCs, when intro-
duced to the cells as either dissolved salt or incorporated
into CaP coatings. Importantly, the positive effect of stron-
tium appears to synergistically increase when used in com-
bination with CaP coatings. Overall, this study supports the
use of Sr21-incorporated CaPs as potential synthetic bone
graft substitutes.
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